Gilead Sciencesvs.United Therapeutics
GILD vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 7.0× larger than United Therapeutics by market cap; year to date, United Therapeutics leads (+12.3% vs +5.8%).
Side by side
| GILD | UTHR | |
|---|---|---|
| Market cap | $162B | $23.2B |
| Price | $129.83 | $547.06 |
| Today | −3.7% | −1.0% |
| Return YTD | +5.8% | +12.3% |
| Return 1Y | +13.3% | +82.3% |
| P/E | 17.5 | 18.0 |
| P/S | 5.4 | 7.3 |
| P/B | 6.9 | 3.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →More comparisons in Biotech & innovation
See where GILD and UTHR sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →